Shilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.
Panelists discuss how the frontline treatment of pancreatic cancer typically involves chemotherapy regimens such as FOLFIRINOX (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin) or gemcitabine-based therapies, with decisions guided by tumor characteristics, patient performance status, and treatment goals, aiming to improve survival outcomes and quality of life in newly diagnosed patients.
Panelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease management and improve quality of life while identifying opportunities to strengthen provider communication and access to resources.
Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.
In a recent Hot Topics article, reimbursement rates for Medicare physicians are discussed, and how it will impact their practice.
Syed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.
Surgeons, radiation oncologists, and medical oncologists gathered to discuss treatment options and approaches for NSCLC.
Kira MacDougall, MD, and Muhammad Rafay Khan Niazi, MD, spoke with CancerNetwork® about their research into the significance of peripheral blood biomarkers of response to immunotherapy in non–small cell lung cancer published in the journal ONCOLOGY®.
Dr Choudhury shares recent updates from 2021 meetings including ASCO GU, AUA, and ESMO.
Laurence Albigès, MD, PhD, discusses how immunotherapy combinations have affected the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.
CancerNetwork® spoke with Quita Highsmith and Monica Baskin, MD, about the Advancing Inclusive Research Alliance and efforts to include more diverse populations in clinical trials.
Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
The panel shares closing advice for patients with multiple myeloma receiving teclistamab, and community providers and nurse practitioners administering teclistamab to patients.
Samuel Edwards, MD, discusses the science behind physician burnout and how it can be prevented.
Examine the efficacy and safety of the BCMA-targeting bispecific antibody elranatamab as monotherapy and in combinations from the Phase 2 MagnetisMM-3 trial in patients with relapsed or refractory multiple myeloma.
Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.